<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Alpha-synuclein is the major constituent of <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> found in neurons in <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>) and might be of diagnostic value as a biomarker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesized that, as a consequence of increased accumulation of alpha-synuclein intraneuronally in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>, the levels of alpha-synuclein in cerebrospinal fluid (CSF) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> patients would be lower than in other <z:hpo ids='HP_0000726'>dementias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Our objective was to investigate the CSF levels of alpha-synuclein in several <z:hpo ids='HP_0000726'>dementia</z:hpo> disorders compared to control levels and to investigate the diagnostic value of CSF alpha-synuclein as a marker to discriminate between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> and other types of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed the levels of alpha-synuclein in CSF of 40 DLB patients, 131 patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, 28 patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, and 39 patients with <z:hpo ids='HP_0002145'>frontotemporal dementia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We did not find any significant differences in CSF alpha-synuclein levels between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> patients and patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> or <z:hpo ids='HP_0002145'>frontotemporal dementia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that in clinically diagnosed patients, alpha-synuclein does not appear to be a useful biomarker for the differentiation between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> and other types of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>